What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
About
Headquartered in Shanghai, China, PeptideXpo controls the line from synthesis to QC — we manufacture and document peptides rather than resell them, which is what lets global buyers audit us. Our buyers include compounding pharmacies, med-aesthetic brands, research labs, biotech / pharma R&D groups, and distributors operating across multiple regions.
Our Facility
The video below is a 30-second walk-through of our active vial-filling line in Shanghai — same line every order ships from. No stock footage.
Vial-filling line · 30s walk-through
Captured on-site during a production day in Shanghai. No stock footage. For the full facility walkthrough see our Facility page.
Quality beyond purity
Most suppliers quote one purity figure and stop. We evaluate every batch across the dimensions that actually decide whether a peptide performs — and document each one on the COA.
Each lot is checked to reproduce the previous batch — not a one-time good result.
ESI / LC-MS confirms the molecule matches the label before release.
Net-peptide content is reported, so you buy peptide — not salt and water.
A defined visual specification is checked on every release.
Bacterial endotoxin (LAL) testing available for in-vivo and injectable work.
Sterile vial filling for the products and markets that require it.
A stability program backs the re-test dating printed on each COA.
How we're organized
PeptideXpo is structured so every buyer-facing decision, pricing, lead time, COA, regulatory review, passes through people who own the relevant function. Inquiries land with sales, but quality and regulatory review every quote before it goes out.
Function
Oversees synthesis, purification, lyophilization, vial filling, and packaging across all production lines. Final sign-off on production schedules and shop-floor changes.
Tenure
10–15 years in synthetic peptide manufacturing
Background
Solid-phase peptide synthesis at a major Chinese CDMO; pharma-API process development for both research-grade and pharmacy-grade material.
Function
Owns analytical methods, stability program, batch release, and COA approval workflow. No batch ships without QA sign-off on the analytical packet.
Tenure
8–12 years in pharmaceutical QA
Background
Documented analytical method development (HPLC, mass spec, Karl Fischer, LAL endotoxin); USP/EP/CP method references where applicable.
Function
Sequence design, non-standard modifications (PEG conjugation, lipidation, copper coordination, D-amino-acid incorporation, intramolecular disulfide bridging), pilot-scale process development.
Tenure
12+ years in synthetic peptide R&D
Background
Doctoral-level training in peptide chemistry; prior experience with custom-sequence synthesis for both research and clinical-development programs.
Function
Direct contact for buyers worldwide. Reviews each inquiry for regulatory fit in the destination market before pricing, written advisory on FDA 503A/503B, EMA, MENA / APAC / LATAM frameworks.
Tenure
8–10 years in pharma B2B sales + regulatory
Background
Cross-border peptide-active commercial relationships; regulatory tracking across major markets including FDA PCAC briefings, EMA scientific advice, and national medicines agency import frameworks.
Individual leader identities are disclosed under NDA at the commercial-relationship stage rather than on the public site. Avatars above are monogram-style identifiers, not photographs, they represent the function, not a specific person.
More than a supplier
Most partners reach us with a product concept, not a finished specification — so we work the gap with you: which peptides fit your market and regulatory lane, the fill sizes and documentation your channel needs, packaging built for your launch, and a supply plan that keeps it on the shelf. We do this for partners across North America, Europe, Asia-Pacific, Australia, and the Middle East.
Which peptides fit your market, positioning, and regulatory lane.
Fill sizes, salt form, and the COA / spec set your channel expects.
Vial, label, and presentation built for your launch.
Locked specs and lead times so a launched product stays in stock.
What you can order
We manufacture and document the full range below. Tell us what you're building and our team scopes it — quality and regulatory review every quote before a price goes out.
Catalog peptides in standard fill sizes, batch-documented with a COA.
Synthesis, purification, lyophilization and vial filling under one quality system.
Sterile filling where the product or destination market requires it.
Produced to your specification and labeling — your brand on the vial.
We develop the formulation or sequence; you take it to market.
Your branding, packaging and documentation package.
Vial format, labeling, cartoning and insert options.
Locked specifications and pricing across recurring campaigns.
How we work
The manufacturing behind PeptideXpo has run since 2013, beginning as a peptide-synthesis operation supplying research-grade material to academic labs and CROs, and growing into an end-to-end peptide manufacturer in China, covering synthesis, chromatography purification, lyophilization, vial filling, and packaging under a single quality system.
Today, the same facility produces material for compounding pharmacies, cosmetic and med-aesthetic OEM clients, biotech R&D groups working on custom sequences, and a distributor network across multiple regions.
Our positioning is deliberately not the cheapest in the market. We invest in documentation (batch-specific COA, HPLC + Mass Spec, sequence verification, stability studies) and in regulatory awareness, every quote is reviewed for fit with the destination market's rules before pricing.
We are actively tracking the FDA Pharmacy Compounding Advisory Committee review of seven peptides expected in July 2026 (BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon) and have already aligned our documentation depth with the standards the 503A bulks list will demand.
A first reply within 24 hours · Catalog · Sample COA · MOQ · Lead time. Our regulatory and sales teams read every inquiry before any price goes out.
